Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $1.95B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 2.32M
Average 2.47M
BHVN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Biohaven Ltd.NYSE: BHVN
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 43.6% from a year ago
Cash & equivalents stood at $238.03M at the end of Q2 FY2026, up 43.6% from a year earlier and down 12.8% from the prior quarter. Over 3 fiscal years it compounded at +3.9% a year.
Context
- Cash & equivalents amounted to 64.2% of total assets at the end of Q2 FY2026, up 34.1 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +43.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 229.96M USD
- Year-over-year change
- +132.0%
- 4-year CAGR
- +31.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 229.96M | +132.0% |
| FY2024 | 2024-12-31 | 99.13M | -60.1% |
| FY2023 | 2023-12-31 | 248.4M | +21.2% |
| FY2022 | 2022-12-31 | 204.88M | +169.4% |
| FY2021 | 2021-12-31 | 76.06M | — |
Cash & Equivalents vs competitors
How BHVN compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +43.6% is the 4th highest of 11, against a peer median of -2.8%.
- Cash & equivalents amounts to 64.2% of total assets for BHVN, versus a peer median of 24.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $500.22M USD | +154.5% | +18.1% | 66.9% | |
| Mar 2026 | $452.68M USD | -5.1% | +5.1% | 42.2% | |
| Sep 2026 | €282.73M EUR | -14.1% | +21.7% | 95.8% | |
| Jun 2026 | $238.03M USD | +43.6% | +3.9% | 64.2% | |
| Sep 2026 | $212.84M USD | -21.9% | +218.0% | 42.1% | |
| Sep 2026 | $163.8M USD | +97.0% | -30.7% | 10.9% | |
| Mar 2026 | $134.7M USD | +6.2% | -33.3% | 17.8% | |
| Mar 2026 | $111.75M USD | +91.2% | -3.1% | 28.5% | |
| Mar 2026 | $63.32M USD | -23.4% | +2.2% | 20.8% | |
| Jun 2026 | $48.88M USD | -0.5% | +101.3% | 9.2% | |
| Sep 2026 | $26.95M USD | -25.2% | -0.6% | 3.7% | |
| Peer median (excluding BHVN) | — | -2.8% | +3.6% | 24.6% | |
Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 76.06M | 204.88M | 248.4M | 99.13M | 229.96M |
| Short-term Investments | 0 | 260.46M | 133.42M | 386.86M | 89.18M |
| Net Receivables | 0 | 46.14M | 13.25M | 2.6M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 12.03M | 54.54M | 12.13M | 508K | 2.17M |
| Total Current Assets | 94.82M | 586.97M | 442.45M | 538.47M | 368.33M |
| Property, Plant & Equipment (Net) | 17.68M | 52.44M | 48.58M | 53.71M | 15.96M |
| Goodwill | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M |
| Intangible Assets | 18.95M | 18.4M | 18.4M | 18.4M | 18.4M |
| Long-term Investments | 6M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.22M | 2.59M | 2.4M | 3.13M | 47.36M |
| Total Non-current Assets | 47.24M | 74.82M | 70.77M | 76.64M | 83.12M |
| Total Assets | 142.06M | 661.78M | 513.21M | 615.11M | 451.45M |
| Account Payables | 4.78M | 10.7M | 15.58M | 18.03M | 11.64M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 9.54M | 14.6M | 35.7M | 84.71M | 59.49M |
| Total Current Liabilities | 41.94M | 90.02M | 55.42M | 154.23M | 115.93M |
| Long-term Debt | 0 | 0 | 0 | 0 | 238.9M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.64M | 2.41M | 2.25M | 4.66M | 4.58M |
| Total Non-current Liabilities | 5.44M | 32.99M | 29.81M | 37.45M | 283.44M |
| Total Liabilities | 47.37M | 123.01M | 85.24M | 191.67M | 399.38M |
| Common Stock | 34.69M | 615.74M | 887.53M | 1.66B | 1.93B |
| Retained Earnings | 0 | (91.12M) | (499.29M) | (1.35B) | (2.08B) |
| Accumulated OCI | 0 | 284K | (65K) | 79K | 8.35M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 60M | 0 | 0 | 0 | 0 |
| Total Equity | 94.69M | 538.77M | 427.98M | 423.44M | 52.07M |
| Total Debt | 3.24M | 33.6M | 30.88M | 36.58M | 284.61M |
| Net Debt | (72.82M) | (171.28M) | (217.53M) | (62.55M) | 54.66M |
Biohaven Ltd.
NYSE:BHVN
Intrinsic Alpha fair value
Locked
Current Price
$12.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.